LYCADEX® BioPharma - Dextrose monohydrate, low endotoxin, USP, EP, JP

PEARLITOL® CR-H co-processed mannitol HPMC is a direct compression excipient providing functional properties of binder as well as controlled release to your tablet. PEARLITOL® CR-H can be used in both pharmaceutical and nutraceutical oral dosage forms.

PEARLITOL® 200 INH mannitol has all the key attributes for its use as an effective carrier in drypowder inhalers (DPI).Key benefits:
• Narrow particle size distribution
• Suitable particle size as inhalation carrier
• Enhances drug formulation stability
• Reduced chemical interactions with APIs...

Delivering secure supply with the right partner. Trust is the most essential ingredient.

Maltodextrins and dried glucose syrups are starch hydrolysis products with a dextrose equivalent. GLUCIDEX® is a carbohydrate source in infant and enteral foods.

A range of superdisintegrants for different formulation needs.

Suitable for use in biopharmaceutical manufacturing and as an excipient for injectable dosage forms.

This excipient is used as filler for gelatin capsules and binder for direct compression. LYCATAB® C and C-LM combines the disintegration power of starch grains with the high cohesion and good compressibility.

Partially hydrolyzed starch for solid dosage forms, used as a binder for wet granulation and as diluent for direct compression.

Natural pregelatinized starch LYCATAB® PGS: solid dosage forms. This excipient is used as a binder for wet granulation.

Roquette’s LYCOAT® range is a major breakthrough in aqueous film coating and film forming.

Native starches of plant origins : Maize, wheat and potato. Extra white maize starch has a disintegration function and can be used as insoluble diluents.

Delivering secure supply with the right partner. Trust is the most essential ingredient.

The new facility will focus on the research of excipients for oral dosage forms, drug delivery systems, nutraceutical APIs and innovative pharma ingredients

Discover the wide range of products by Roquette in Pharmaceuticals and Neutraceuticals

The ramping up of vaccine manufacturing demand amid the COVID-19 pandemic had an initial impact on cell and gene therapy production but the regenerative medicine sector has largely weathered the storm, according to senior industry figures in a recent panel discussion at the CPHI Festival of Pharma virtual event.

Worldwide, people are increasingly health-conscious and aware of the impact of individual lifestyle choices on their health and the health of others. In the latest years, consumers seek more and more transparency from companies through their brand, product manufacturing, and actions that promote well-being for the world around them. While also looking for more affordable, accessible, and personalized product experiences. This session explores the latest news and insight on consumer health, including how pharma engages patients in education and decision-making.

It’s a hard pill to swallow, but medication adherence is a crucial issue today. For oral formulations in pharma and nutraceuticals, taste, appearance, and aroma directly impact patient compliance and consumer experience.
Choosing the right excipients to provide optimum performance while continuing to appeal to patients and consumers alike is critical in bringing finished formulations to market.

Polysorbates are intensively used in biologics formulation as stabilizer due to their propensity to inhibit aggregation at interfaces but possess low intrinsic stability. In this study, the chemical stability of KLEPTOSE® HPBCDs are compared with polysorbates under various stress conditions.

When subjected to heat stress and other chemical stressors – autoclave, light and oxidative stresses – HPBCD remains almost stable while polysorbates show more severe degradation. Further, profiling characterization and degradation analysis reveal that HPBCD chemical structure remains intact while polysorbates undergo significant hydrolytic degradation and oxidation.

Lastly, the physicochemical stability of monoclonal antibody in formulations have been investigated using adalimumab as a model protein. When subjected to light stress, HPBCD-containing formulations show significant decreases in protein aggregation, as well as superior monomer and total protein recovery compared to polysorbate-containing formulations. HPBCD also reduces both agitation and thermal stress-induced protein aggregation and prevents sub-visible particle formation compared to polysorbates.


Click here to register

Introducing LYCAGEL™️, Roquette’s new vegetarian softgel innovation that is truly unique, formulated with a film forming component derived from hydroxypropyl pea starch technology. This high-performance solution for softgel compositions provides clear and shiny softgels that are strong and durable, with seal integrity to prevent leaker defects. LYCAGEL is the first vegetarian softgel solution acceptable for both nutraceutical supplement and pharma USP/EP applications. The company’s sell sheet provides further information, including application data, on this new solution, ready to take your innovation to the next level.

Unleashing the power of cyclodextrins within vaccine formulation development. HPβCD is back in the spotlight, with formulators looking again at a familiar ‘ready to go’ excipient that could be part of the solution to speed up early stage vaccine development. If you would like to know more about how cyclodextrins could form part of your program, please contact our experts. https://www.roquette.com/biopharma-low-endotoxin-hydroxypropyl-beta-cyclodextrin

Learn more about Roquette´s new online technical search platform, Innovation Hub, a virtual destination for formulators to get what they need at the click of a button. As a part of Innovation Hub, please also meet Rosa, a new virtual technical assistant which help users to search formulation, read our research on direct compression, and directly get in touch with our Technical Support team. For more information and to try Innovation Hub for yourself, please visit: www.roquette.com/innovation-hub

At Roquette, as a world class supplier of plant-based products and an innovative solutions provider to pharmaceuticals, biopharmaceuticals and dietary supplement markets, we work every day to formulate for a healthier world together with our suppliers, customers and partners. At Roquette, our commitment is based on our key principles of credibility, reliability and trust. With our wide portfolio of excipients, we offer our customers technical support and high quality standards to build a healthier future together. Please join us.

Roquette has recently identified that its KLEPTOSE®️ hydroxypropyl beta-cyclodextrins (HPβCD) product, a functional excipient and a specialty active pharmaceutical ingredient (API), may be effective to help the joint efforts of the scientific and pharmaceutical communities working on treating and preventing new emerging viruses such as the coronavirus. HPβCD can effectively act as a safe, enabling excipient for solubility enhancement of antiviral drugs, stability improvement of therapeutic monoclonal antibodies, and as a vaccine adjuvant. KLEPTOSE®️ is a cyclodextrin, a group of structurally related natural products formed during bacterial digestion of cellulose. Cyclodextrins have indeed been shown to be effective as solubilizing and stabilizing agents in vaccines, monoclonal antibodies and oral formulations. Moreover, cyclodextrins can potentially be used for infection containment or as virucidal agents after structural modification. The company’s new position paper speaks to the potential role of cyclodextrins, such as HPβCD, in detail: “Combating Coronavirus: Key Role of Cyclodextrins in Treatment and Prevention.”

KLEPTOSE® HPB-LB is a hydroxypropyl beta-cyclodextrin parenteral grade material that is used as an encapsulating agent for Rx injectables. It is a modified betacyclodextrin for parenteral use.

Discover how Roquette brings new solutions to Biopharmaceuticals